FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003877025> ?p ?o ?g. }

• W3003877025 endingPage "56" @default.
• W3003877025 startingPage "56" @default.
• W3003877025 abstract "Background: Recurrent respiratory papillomatosis (RRP) is a rare disorder characterized by the generation of papillomas of the aerodigestive tract, usually associated with human papilloma virus (HPV) subtypes 6, 11. INO-3106 is a DNA plasmid-based immunotherapy targeting E6 and E7 proteins of HPV6, in order to create a robust immune T cell response. Methods: Testing of INO-3016 in animal models confirmed immunogenicity of the DNA-based therapy. A single-site open-label Phase 1 study was initiated for patients with HPV6-positive RRP. Patients were dosed with INO-3106 with or without INO-9012, a DNA plasmid immunotherapy that encodes IL-12, delivered intramuscularly (IM) in combination with electroporation (EP) with the CELLECTRA® device. Patients received an escalating dose of INO-3106, 3 mg once and then 6 mg for three additional doses, each dose three weeks apart, with the third and fourth doses co-administered with INO-9012. The primary objective of the study was to evaluate the safety and tolerability of INO-3106 with and without INO-9012. The secondary objective was to determine cellular immune responses to INO-3106 with and without INO-9012. Exploratory objectives included preliminary clinical efficacy to the therapy. Results: Three patients were enrolled in this study, of which two had RRP. Study therapy was well-tolerated, with no related serious adverse events and all related adverse events (AEs) were low-grade. Injection site pain was the most common related AE reported. Immunogenicity was evidenced by multiple immune assays showing engagement and expansion of an HPV6-specific cellular response, including cytotoxic T cells. Preliminary efficacy was demonstrated in patients with RRP in the form of reduction in need for surgical intervention for papilloma growth. Prior to intervention, both patients required surgical intervention approximately every 180 days. One patient demonstrated a greater than three-fold increase in surgery avoidance (584 days) and the other patient remains completely surgery-free as of the last contact at 915 days, a greater than 5-fold increase in surgery interval. Conclusion: INO-3106 with and without INO-9012 was well tolerated, immunogenic and demonstrated preliminary efficacy in patients with HPV6-associated RRP aerodigestive lesions. Further clinical study is indicated." @default.
• W3003877025 created "2020-02-07" @default.
• W3003877025 creator A5012109068 @default.
• W3003877025 creator A5014787955 @default.
• W3003877025 creator A5015582820 @default.
• W3003877025 creator A5023265367 @default.
• W3003877025 creator A5025867351 @default.
• W3003877025 creator A5034146116 @default.
• W3003877025 creator A5045028558 @default.
• W3003877025 creator A5049161916 @default.
• W3003877025 creator A5056098854 @default.
• W3003877025 creator A5061408818 @default.
• W3003877025 creator A5062034160 @default.
• W3003877025 creator A5063297176 @default.
• W3003877025 creator A5067843924 @default.
• W3003877025 creator A5067915183 @default.
• W3003877025 creator A5071608389 @default.
• W3003877025 creator A5071855162 @default.
• W3003877025 creator A5074185619 @default.
• W3003877025 creator A5079743464 @default.
• W3003877025 date "2020-01-29" @default.
• W3003877025 modified "2023-09-27" @default.
• W3003877025 title "Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis" @default.
• W3003877025 cites W1597586910 @default.
• W3003877025 cites W1688526230 @default.
• W3003877025 cites W1881707187 @default.
• W3003877025 cites W1982799171 @default.
• W3003877025 cites W2003990673 @default.
• W3003877025 cites W2004962555 @default.
• W3003877025 cites W2016097275 @default.
• W3003877025 cites W2021580977 @default.
• W3003877025 cites W2031366757 @default.
• W3003877025 cites W2037089018 @default.
• W3003877025 cites W2055801337 @default.
• W3003877025 cites W2060713773 @default.
• W3003877025 cites W2061624417 @default.
• W3003877025 cites W2081841705 @default.
• W3003877025 cites W2082323859 @default.
• W3003877025 cites W2084065908 @default.
• W3003877025 cites W2086107770 @default.
• W3003877025 cites W2108961289 @default.
• W3003877025 cites W2120689002 @default.
• W3003877025 cites W2127342594 @default.
• W3003877025 cites W2128416381 @default.
• W3003877025 cites W2128471759 @default.
• W3003877025 cites W2129081421 @default.
• W3003877025 cites W2166494739 @default.
• W3003877025 cites W2170704251 @default.
• W3003877025 cites W2323034952 @default.
• W3003877025 cites W2559662677 @default.
• W3003877025 cites W2756879089 @default.
• W3003877025 cites W2765931561 @default.
• W3003877025 cites W2849303123 @default.
• W3003877025 cites W2891596321 @default.
• W3003877025 cites W2923460756 @default.
• W3003877025 cites W2944669628 @default.
• W3003877025 cites W2947622268 @default.
• W3003877025 cites W4200455332 @default.
• W3003877025 doi "https://doi.org/10.3390/vaccines8010056" @default.
• W3003877025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7158680" @default.
• W3003877025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32013270" @default.
• W3003877025 hasPublicationYear "2020" @default.
• W3003877025 type Work @default.
• W3003877025 sameAs 3003877025 @default.
• W3003877025 citedByCount "13" @default.
• W3003877025 countsByYear W30038770252020 @default.
• W3003877025 countsByYear W30038770252021 @default.
• W3003877025 countsByYear W30038770252022 @default.
• W3003877025 countsByYear W30038770252023 @default.
• W3003877025 crossrefType "journal-article" @default.
• W3003877025 hasAuthorship W3003877025A5012109068 @default.
• W3003877025 hasAuthorship W3003877025A5014787955 @default.
• W3003877025 hasAuthorship W3003877025A5015582820 @default.
• W3003877025 hasAuthorship W3003877025A5023265367 @default.
• W3003877025 hasAuthorship W3003877025A5025867351 @default.
• W3003877025 hasAuthorship W3003877025A5034146116 @default.
• W3003877025 hasAuthorship W3003877025A5045028558 @default.
• W3003877025 hasAuthorship W3003877025A5049161916 @default.
• W3003877025 hasAuthorship W3003877025A5056098854 @default.
• W3003877025 hasAuthorship W3003877025A5061408818 @default.
• W3003877025 hasAuthorship W3003877025A5062034160 @default.
• W3003877025 hasAuthorship W3003877025A5063297176 @default.
• W3003877025 hasAuthorship W3003877025A5067843924 @default.
• W3003877025 hasAuthorship W3003877025A5067915183 @default.
• W3003877025 hasAuthorship W3003877025A5071608389 @default.
• W3003877025 hasAuthorship W3003877025A5071855162 @default.
• W3003877025 hasAuthorship W3003877025A5074185619 @default.
• W3003877025 hasAuthorship W3003877025A5079743464 @default.
• W3003877025 hasBestOaLocation W30038770251 @default.
• W3003877025 hasConcept C104317684 @default.
• W3003877025 hasConcept C126322002 @default.
• W3003877025 hasConcept C186852380 @default.
• W3003877025 hasConcept C197934379 @default.
• W3003877025 hasConcept C203014093 @default.
• W3003877025 hasConcept C2777701055 @default.
• W3003877025 hasConcept C2778375690 @default.
• W3003877025 hasConcept C2780868878 @default.
• W3003877025 hasConcept C2910019179 @default.

• next